Impact of Morning Light Therapy in IBD
Part of paid clinical trials in New York, New York.
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Study ID
- NCT07207200
- Status
- Recruiting
Conditions
- Inflammatory Bowel Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Morning Light Therapy — DEVICEOne hour of morning light therapy each day for four weeks
Study Details
The pilot study will focus on the effects of morning light therapy (MLT) in adult patients with ulcerative colitis (UC) who have evidence of poor sleep quality and active inflammation. The specific population is at risk for circadian rhythm sleep-wake disorders and has significant potential benefit from circadian realignment, which may lead to improved sleep quality and, ultimately, UC-related inflammatory activity. During an initial one-week lead-in period, participants will obtain baseline circadian-related labs, complete symptom-related surveys, and use a wearable device continuously to obtain baseline sleep-wake data. After the lead-in week, patients will undergo one hour of MLT while wearing wearable devices continuously and completing daily symptom surveys. At the end of four weeks of MLT, patients will obtain post-intervention circadian and inflammatory assessments in addition to completing the same symptom-related surveys.
Key Dates
- Start date
- Mar 31, 2026
- Status verified
- Mar 2026
- Primary completion
- Jul 1, 2027
- Completion
- Jul 1, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Adult patients with Ulcerative Colitis (UC)Adult patients with ulcerative colitis (UC)
Primary Outcome Measure
C-reactive protein (CRP) level [ Time Frame: week 4 ]
Central Contacts
- Hyder Said212-824-7786
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mount Sinai Hospital | New York | New York | 10029 | Hyder Said 212-824-7786 Hyder Said (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal InflammationRecruiting · Icahn School of Medicine at Mount Sinai · New York, New York
- A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved IndicationPHASE4 · Not Yet Recruiting · Eli Lilly and Company · Glenview, Illinois
- Immune Regulation in Ulcerative Colitis or Crohn s DiseaseRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland